


## PHARMACEUTICAL 2020

## Stoke Therapeutics Inc. Rank 13 of 358





## PHARMACEUTICAL 2020



## Stoke Therapeutics Inc. Rank 13 of 358

The relative strengths and weaknesses of Stoke Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Stoke Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 63% points. The greatest weakness of Stoke Therapeutics Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 18% points.

The company's Economic Capital Ratio, given in the ranking table, is 304%, being 267% points above the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	226,033
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	4,101
Liabilities, Non-Current	221
Other Assets	205
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	3,353
Other Revenues	0
Property and Equipment	2,512
Research and Development	23,764
Selling, General and Administrative Expense	11,914

Output Variable	Value in 1000 USD
Assets	228,750
Liabilities	4,322
Expenses	35,678
Revenues	0
Stockholders Equity	224,428
Net Income	-32,325
Comprehensive Net Income	-32,325
Economic Capital Ratio	304%

